• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 514870 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1419297563 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1419297563 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Shares of United Therapeutics Under Pressure, Down 2.1%

Published on Mon, 06/10/2013 - 10:55
By Robert Cotter

United Therapeutics (NASDAQ:UTHR) is one of today's biggest movers, down 2.1% to $65.57. The Dow is trading fractionally higher to 15,261 and the S&P is currently trading fractionally higher to 1,645.

United Therapeutics (NASDAQ:UTHR) is currently priced 10.4% above its average consensus analyst price target of $58.78. The stock should discover initial support at its 50-day moving average (MA) of $64.26 and subsequent support at its 200-day MA of $57.05.

United Therapeutics share prices have moved between a 52-week high of $70.74 and a 52-week low of $36.55 and are now trading 79% above that low price at $65.57 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.4% while the 50-day MA has advanced 0.7%.

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

Watch for Continued Gains in Shares of T...

Shares of T Rowe Price (NASDAQ:TROW) traded today at $87.45, breaking its 52-week high. ...

Shares of TriQuint Semiconductor Rise to...

Shares of TriQuint Semiconductor (NASDAQ:TQNT) traded today at $27.36, breaking its 52- ...

TJX Cos: The Winning Streak Continues (T...

TJX Cos (NYSE:TJX) traded today at a new 52-week high of $67.49. This new high was rea ...

TreeHouse Foods: The Winning Streak Cont...

Shares of TreeHouse Foods (NYSE:THS) traded at a new 52-week high today of $88.52. So ...

Recent 52-Week High Exceeded in Shares o...

Taser International (NASDAQ:TASR) traded at a new 52-week high today of $26.39. So far ...

TravelCenters of America Looks to Contin...

Shares of TravelCenters of America (AMEX:TA) traded at a new 52-week high today of $12. ...

Recent 52-Week High Exceeded in Shares o...

Shares of Sensient Technologies (NYSE:SXT) traded at a new 52-week high today of $61.74 ...

Watch for Continued Gains in Shares of S...

Shares of Skyworks Solutions (NASDAQ:SWKS) traded today at $74.18, breaking its 52-week ...